Lee, Sang Eun <br/><br/>
Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.  [electronic resource] 

 -  Clinical therapeutics  Mar 2012 
 - 552-568, 568.e1-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-114X 
<br/><br/><label>Standard No.: </label>10.1016/j.clinthera.2012.01.024  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Angiotensin Receptor Antagonists--administration & dosage<br/>Antihypertensive Agents--administration & dosage<br/>Biphenyl Compounds--adverse effects<br/>Blood Pressure--drug effects<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Hypertension--diagnosis<br/>Losartan--administration & dosage<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Pyrimidines--adverse effects<br/>Republic of Korea<br/>Severity of Illness Index<br/>Tetrazoles--adverse effects<br/>Treatment Outcome<br/>Young Adult